Home › Actinium Completes Technology Transfer For Manufacturing Of Its Lead Drug Candidate Iomab-B
 

Keywords :   


Actinium Completes Technology Transfer For Manufacturing Of Its Lead Drug Candidate Iomab-B

2013-12-30 05:54:18| drugdiscoveryonline Home Page

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has successfully transferred the technology for the manufacture of Iomab-B (BC8-I-131), a drug being developed for therapeutic treatment of incurable blood cancers

Tags: technology lead transfer drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05The man who turned his dead father into a chatbot
16.05Firms leaving UK 'not a crisis' says stock market boss
15.05Exploring the future of agriculture
15.05American, Mexican, and Canadian cattle producers sign joint statement
15.05Attitudes EWG Verified Skincare Line Oceanly Expands with SPF Offerings
15.05Sherwin-Williams Packaging Coatings Expands Non-BPA Coatings Production in Europe
More »